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y facts Roux-en-Y gastric bypass
 ↓ Appetite
 ↓ Energy intake
↓ Glucotoxicity
 ↓ Insulin 
resistance
↑ Insulin secretion
↓  Glucose output
 ↑ Activation of genes such as
PPARα/γ 
→ enchance hepatic fatty oxidation
→ lipid export
→ insulin sensitivity
Early nutrient contact
 with ileum: ↑ PYY
 Modification 
of gut flora
 ↓ Iron absorption
GB mechanisms and pathways
ture
 Obesity increases the risk of NAFLD
Batriatric surgery should be considered for patients: 
• with a body mass index >40 
• who wish to lose weight 
Bariatric surgery
• induces long-term weight loss
• decreases morbidity
• decreases the incidence of cancer
• decreases mortality
• shows a sustained decrease in steatosis
• do not appear to be associated with development of 
extensive fibrosis
• may improve ballooning and inflammation; (larger 
studies are warranted to confirm this conclusion).
• Is one of the most efficient methods for 
losing weight
• RYGB achieves its physiological 
benefits through “BRAVE” effects:
Bile flow alteration, 
Reduction in gastric size, 
Anatomical rearrangement,
Vagal manipulation and subsequent 
Enteric gut hormone modulation
•  Bariatric surgery is a powerful 
treatment for insulin resistance, with a 
remission in 42% of cases after  RYGB 
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↓ Liver 
inflammation
Bariatric surgery, as an indication, for the treatment 
of NASH in morbid obesity has to be proved and 
confirmed
Long-term (10 yr) efficiency and safety data on liver 
histology after bariatric surgery are warranted
The choice of the best bariatric procedure (RYGB, 
gastric banding, sleeve gastrectomy...) has to be 
precise for NASH
Regarding the worldwide epidemiology, bariatric 
surgery for morbidly obese patients with cirrhosis 
seems to be a future challenge
↓ Steatosis
 ↓ Insulin 
resistance
↑GPL-1
↑GPL-1
 ↑Secretins
Brain
Liver
Intestine
Roux-en-Y gastric bypass
(RYGB)Adipose tissue
↑ Adiponectin
New intestinal microbia
Proteobacteria >> Firmicutes
Between 85-90% of the candidates for 
bariatric surgery have steatosis
Steatosis is improved in 90% of cases 
after surgery
→ Changes in energy metabolism
→ ↑↑ production in short-chain fatty acids 
→ ↑ expression of key mediators 
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Obesity increases the risk of NAFLD (non-alcoholic fatty liver disease). 
Bariatric surgery should be considered for severely obese persons with 
a body mass index (BMI) higher than 40 (or 35 if co-morbidity is pre-
sent) and who clearly wish to lose weight. It induces long-term weight 
loss and decreases morbidity, the incidence of cancer, and mortality. 
Compelling data consistently show a sustained decrease in steatosis, 
whereas an evolution in ballooning, necro-inflammatory features, and 
fibrosis remains subject to debate.
   Bariatric surgery is the most efficient method for losing weight. Mal-
absorptive procedures (Roux-en-Y gastric bypass (RYGB) or duodenal 
switch) induce greater weight loss than restrictive procedures (laparo-
scopic gastric banding (LAGB)), with a range of around 60% of excess 
weight [1]. These variations may be due to differing physiological ef-
fects. LAGB and sleeve gastrectomy (SG) promote satiation via stretch 
mechano-receptor activation, with an additional effect after SG related 
to partial removal of fundus, a secretion site of ghrelin, an orexigenic 
hormone. Conversely, RYGB acts via several pathways, including early 
contact of nutrients with the ileum and increased secretion of PYY, an 
anorectic hormone, and incretins (GLP-1, GLP-2) involved in the en-
teroinsular axis. For example, GLP-1 stimulates insulin secretion and 
decreases hepatic glucose output and insulin resistance in the liver and 
adipose tissues. GLP-1 also decreases steatosis via activation of genes 
such as PPARα/γ that enhance hepatic fatty oxidation, lipid export, and 
insulin sensitivity. GLP-1 lowers liver inflammation via the attenuation of 
TNFα, IL-6, IL-1β, and MCP-1 expression [2]. More recently, GLP-1 ap-
peared to reduce fatty-acid-related hepatocyte death through activation 
of macro- and chaperon-mediated autophagy that reduces endoplas-
mic reticulum stress and liver fatty acid accumulation responsible for 
apoptotic liver injuries [3]. RYGB also affects insulin resistance through 
an increase in adiponectin and changes in gut microbiota secondary to 
alterations in bile and nutrient flow. The new intestinal microbiota, with 
fewer Firmicutes and more Proteobacteria, change energy metabolism, 
directing oligosaccharide metabolism to higher production of short-
chain fatty acids (propionate, acetate, etc.) that stimulate expression of 
key mediators of insulin sensitivity (see Figure) [4].
   Between 85% and 90% of bariatric surgery candidates have steatosis, 
which can be severe (i.e., present in more than two-thirds of hepato-
cytes) in 27% of them [5,6]. Meta-analysis revealed steatosis improve-
ment in 90% of cases after surgery [7]. The improvement occurred with-
in the first year and persisted up to five years. Mechanisms involved 
in the evolution of both insulin resistance and steatosis are intimately 
connected. Indeed, bariatric surgery is a powerful treatment for insulin 
resistance, with remission of type 2 diabetes occurring in 42% of cases 
after RYGB [8]. Patients with insulin resistance refractory to surgery 
have a probability of presenting with severe steatosis that is twice as 
high as that of patients with improved insulin resistance [6]. Moreover, 
weight gain relapse occurs in 46–63% of subjects two years after bariat-
ric procedure. As surgical success is linked to drastic changes in eating 
habits, weight gain may be secondary to psychological disorders, dilata-
tion of the gastric pouch, an increase in volume intake or a sedentary 
lifestyle [9]. As a consequence, future prospective studies must evalu-
ate its impact on liver injury over a follow-up of longer than 5 years.
   Cochrane meta-analysis was unable to evaluate the specific impact 
of bariatric surgery on NASH features [7]. Indeed, most studies had 
insufficient sample sizes and their designs lacked sequential biopsies 
focusing on NASH patients. In a princeps study of 23 NASH patients 
treated with LAGB, necro-inflammatory activity and fibrosis improved in 
approximately 80% of cases [10]. Other clinical and experimental stud-
ies showed the same trend in improvement of NASH and a decrease in 
key inflammatory mediators such as IL8 and MCP1 (measured by RT-
PCR from liver samples) [11], but their sample sizes were insufficient for 
obtaining valid conclusions (Table 1).
   Concern about worsening of fibrosis stems from ileojejunal bypass, a 
no-longer-used procedure that produced up to 7–10% cirrhosis at long 
term (5 years), related, in part, to bacterial overgrowth and translocation 
[12]. Recent procedures do not appear to be associated with develop-
ment of extensive fibrosis [10]. A slight increase in fibrosis in patients 
who were poor responders to bariatric surgery has been described. A 
decrease in collagen-alpha-1, TGFβ1, SMA, a tissue inhibitor of met-
alloproteinase 1 expression and SMA content (measured by RT-PCR 
from liver samples), supports the beneficial effects of current surgical 
procedures [11]. Nevertheless, additional studies are required to deter-
mine whether fibrosis progresses in patients treated with current surgi-
cal procedures.
   Severely obese cirrhotic patients, as compared to non-cirrhotic and 
non-obese cirrhotic patients, have the highest risk of mortality and re-
quire a specific therapeutic strategy possibly involving bariatric surgery. 
However, such an approach warrants discussion. Indeed, malabsorp-
tive procedures are less suitable for cirrhotic patients in light of their 
nutritional status, increased surgical complexity, and absorption of 
drugs, particularly immunosuppressive molecules in the case of liver 
transplantation. Decompensated cirrhotic patients are contraindicated 
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Characteristics of the studies Results
Studies Sample 
size
Surgical 
procedure
Biological 
markers
Steatosis Ballooning Inflammation NASH grade Fibrosis
Barker KB et al., Am J Gastroenterol 2006  19 RYGB no change improved improved improved  improved
Clark JM et al., Obes Res 2005 16 RYGB improved improved improved improved  improved
de Almeida SR et al., Obes Surg 2006 16 RYGB not reported  improved improved  
Dixon JB et al., Hepatology 2004 36 LAGB improved improved improved improved  improved
Dixon JB et al., Obes Surg 2006 60 LAGB improved improved improved improved  improved
Furuya CK et al., J Gastroenterol Hepatol 2007 18 RYGB improved improved   improved
Jaskiewicz K et al., Dig Dis Sci 2006 10 Gastroplasty improved    
Keshishian A et al., Obes Surg 2005 78 Duodenal switch no change improved  improved
Klein S et al., Gastroenterology 2006 7 Bypass no change improved   
Kral JG et al., Surgery 2004 104 Biliopancreatic 
diversion
improved improved   worsened
Liu X et al., Obes Surg  2007 39 RYGB improved improved   
Luyckx FH et al., Int J Obes Relat Metab Disord 1998 69 LAGB not reported improved  worsened  
Mathurin P et al., Gastroenterology 2006 185 Bypass, LAGB improved improved   worsened
Mathurin P et al., Gastroenterology 2009 381 Bypass, LAGB improved improved   worsened
Mattar SG et al., Ann Surg 2005 70 RYGB, LAGB, 
LSG
improved improved  improved  improved
Meinhardt NG et al., Obes Surg 2006 30 Jejuno-ileal 
bypass
no change improved  improved  
Mottin CC et al., Obes Surg 2005 186 RYGB  not reported improved   
Ranløv I et al., Digestion 1990 15 Bypass, 
gastroplasty
improved improved  no change  
Silverman EM et al., Am J Clin Pathol 1995 91 RYGB no change improved   
Stratopoulos C et al., Obes Surg 2005 216 Sleeve improved improved  improved improved improved
Table 1.  Evolution of histological features following bariatric surgery.
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[1for bariatric surgery because of the 21-fold increase in postoperative 
mortality following bariatric procedures [13]. Moreover, the 2-fold mor-
tality increase observed for compensated cirrhotics compared to non-
cirrhotics in the national US database (but not confirmed in other series) 
emphasized that selection criteria for bariatric surgery candidates re-
main to be sharply defined [13]. For some experts, for example, portal 
hypertension evaluated by CT scan and endoscopy, a previous episode 
of hepatic decompensation or biological signs of hepatic insufficiency 
would exclude the possibility of bariatric surgery. All these questions 
warrant further study.
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